Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Non-Small-Cell Lung Cancer: Case Series

被引：1
|
作者：
Gupta, Ashish [1 ,4 ]
Jatwani, Karan [1 ]
Gupta, Kush [2 ]
Qiu, Jingxin [3 ]
Dy, Grace K. [1 ]
机构：
[1] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY USA
[2] Univ Massachusetts, Dept Med, Med Sch Baystate, Springfield, MA USA
[3] Roswell Park Comprehens Canc Ctr, Dept Pathol, Buffalo, NY USA
[4] Roswell Park Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY 14203 USA
来源：
JCO PRECISION ONCOLOGY | 2023年 / 7卷
关键词：
D O I：
10.1200/PO.22.00476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
    Tsurutani, J.
    Park, H.
    Doi, T.
    Modi, S.
    Takahashi, S.
    Nakagawa, K.
    Krop, I.
    Waqar, S.
    Yoh, K.
    Li, B.
    Taira, S.
    Jikoh, T.
    Singh, J.
    Sugihara, M.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S324 - S324
  • [32] Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer
    Hao, Lidan
    Chen, Haiyang
    Wang, Lili
    Zhou, Hanqiong
    Zhang, Zhe
    Han, Jing
    Hou, Jiabao
    Zhu, Yichen
    Zhang, He
    Wang, Qiming
    THORACIC CANCER, 2023, 14 (11) : 1036 - 1041
  • [33] A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation
    Pinquie, Francois
    Cortot, Alexis B.
    Chevalier, Louise-Marie
    Morel, Alain
    Sandrini, Jeremy
    Guguen, Camille
    Morvan, Benjamin
    Molinier, Olivier
    CLINICAL LUNG CANCER, 2022, 23 (02) : E131 - E134
  • [34] Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer
    Patil, Tejas
    Mushtaq, Rao
    Marsh, Sydney
    Azelby, Christine
    Pujara, Miheer
    Davies, Kurtis D.
    Aisner, Dara L.
    Purcell, William T.
    Schenk, Erin L.
    Pacheco, Jose M.
    Bunn, Paul A.
    Camidge, D. Ross
    Doebele, Robert C.
    CLINICAL LUNG CANCER, 2020, 21 (03) : E191 - E204
  • [35] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
  • [36] THE PROGNOSTIC ROLE OF XRCC1, ERCC1, ERCC2, AND TP53 SINGLE NUCLEOTIDE POLYMORPHISMS IN RESECTED NON-SMALL-CELL LUNG CANCER
    Geredeli, C.
    Artac, M.
    Yildirim, S.
    Dede, I.
    Inal, A.
    Guler, T.
    Boruban, M. C.
    Zamani, A.
    Bozcuk, H.
    Demirkazik, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : E50 - E50
  • [37] What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature
    Helissey, Carole
    Favre, Loetitia
    Nguyen, Anh Tuan
    Mamou, Elodie
    Lamboley, Jean-Laurent
    ANTI-CANCER DRUGS, 2022, 33 (01) : E720 - E723
  • [38] Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series
    Zhao, Shuang
    Xian, Xinghong
    Tian, Panwen
    Li, Weimin
    Wang, Ke
    Li, Yalun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [39] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 42, 10.1200/JCO-24-01883, 2024)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (30) : 3635 - 3635
  • [40] PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer
    Riki Okita
    Ai Maeda
    Katsuhiko Shimizu
    Yuji Nojima
    Shinsuke Saisho
    Masao Nakata
    Cancer Immunology, Immunotherapy, 2017, 66 : 865 - 876
12345